Aztreonam-Avibactam Real World Study Against Metallo-ß-lactamase-Producing Carbapenem-Resistant Enterobacterales (AWARE)

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500109207

Enrollment

Unknown

Registered

2025-09-15

Start date

2026-01-01

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complicated intra-abdominal infections or hospital-acquired pneumonia/ventilator-associated pneumonia caused by metallo-ß-lactamase-producing carbapenem-resistant Enterobacterales.

Interventions

Aztreonam-Avibactam Treatment Group:NA

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age 18 years or older; 2. Hospitalized with a diagnosis of confirmed cIAI or HAP/VAP; 3. Confirmed infection with MBL-producing CRE; 4. Received on label use of ATM-AVI treatment for >=24 hours; 5. Informed consent will be obtained or waived.

Exclusion criteria

Exclusion criteria: 1. Confirmed or suspected infection caused by Gram-negative species not expected to respond to ATM-AVI; 2. Currently enrolled in a interventional clinical trial;

Design outcomes

Primary

Measure	Time frame
Clinical Outcomes;	—

Secondary

Measure	Time frame
Microbiological Evaluation;	—

Countries

China

Contacts

Public ContactYunsong Yu

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

yvys119@163.com+86 571 86006660

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026